Sanofi, the French pharmaceutical group whose American Depositary Receipts trade as SNY on the Nasdaq, draws coverage from a broad but divided analyst base. Independent aggregators such as S&P Global and Yahoo Finance report a 12-month average price target near $54.92 across roughly 11 analysts, which rounds to the $55 central target used here. The individual targets span a wide band from about $45 to $63.
That spread reflects genuine disagreement among observers. Cautious, Hold-rated houses sit at the lower end — Morgan Stanley held a $49 target, and Exane BNP Paribas a $50 target, after both moved to neutral ratings. In the middle, TD Cowen maintained a $57 Hold, while more bullish voices such as Berenberg Bank ($62) and Argus Research ($60, Buy) sit near the top. The average is therefore best understood as a midpoint of opinion, not a forecast of a specific outcome, and it should not be read as a published consensus guarantee. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Rating momentum has been choppy. Sanofi received downgrades from Morgan Stanley (to Equal Weight), BNP Paribas (to Neutral), Barclays (to Equal Weight), and Guggenheim (to Neutral) between late 2025 and mid-2026. After the third-quarter report, however, several European brokers raised their euro-denominated targets, and BNP Paribas upgraded the stock back to Outperform — a sign that near-term earnings momentum is reviving confidence.
The ADR last closed near $46.52, leaving a required move of about 18% to reach $55. That is a substantial advance for a low-beta, dividend-paying healthcare name, though it is well within the historical range the shares have traded.
Fundamentally, the path is anchored by Dupixent, the inflammation drug co-marketed with REGN, which continues to beat expectations. Sanofi reported third-quarter 2026 sales growth of 14.3% at constant exchange rates, with business EPS up about 19.6%, and it raised full-year guidance. The shares pay a dividend near $2.42 annually — a yield above 5% at current prices — which provides downside support but also signals a more defensive investor base.
The shares have traded in a 52-week range of roughly $39 to $51. A meaningful resistance level sits near the prior high in the $50–$51 zone, which the stock must clear before the $55 target becomes realistic. On the downside, support has formed near the mid-$40s, with a firmer floor near the $39–$40 area reached in October. The psychological $50 level is likely to act as both a technical and sentiment barrier on the way higher.
Analyst price targets generally reflect a research horizon of about 12 months, though individual analysts use differing periods and assumptions. Investors weighing the $55 target should watch quarterly results and guidance, Dupixent prescription trends, any regulatory decisions across the pipeline, foreign-exchange movements, and further analyst target revisions. The next earnings date, dividend announcements, and key clinical readouts are the most direct catalysts for re-rating the shares. From what I see, tracking these elements closely helps clarify whether the average target holds as a realistic benchmark.
I’ve found Tickeron’s AI Daily Buy/Sell Signals helpful for monitoring names like SNY in real time. The tool uses artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on shifting market conditions and technical behavior. It gives a data-driven way to stay on top of momentum changes without reviewing every chart manually, which fits well into a routine review of healthcare holdings and broader sector trends.
Reaching $55 would require Sanofi to climb roughly 18% from its latest close, a substantial but plausible move if Dupixent keeps compounding and analyst estimates keep rising. The central target is a statistical midpoint of a wide analyst range — roughly $45 to $63 — rather than a single confident forecast, and the recent mix of downgrades followed by target increases shows how divided the Street remains. Strong product momentum and an attractive dividend argue for support, while LOE risk, currency swings, and a heavy $50–$51 resistance zone argue for caution. The outcome will most likely hinge on execution in the immunology franchise and the pace of estimate revisions over the coming quarters. I’m watching this closely as the next few quarters unfold.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
SNY moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend. In 29 of 51 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 57%.
The 10-day moving average for SNY crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.
Following a +0.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNY advanced for three days, in 154 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 51%.
The Aroon Indicator entered an Uptrend today. In 160 of 284 cases where SNY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.
The 10-day RSI Indicator for SNY moved out of overbought territory on November 17, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 10 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 45%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 35 of 68 cases where SNY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 51%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SNY as a result. In 52 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 53%.
The Moving Average Convergence Divergence Histogram (MACD) for SNY turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 19 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 40%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.
SNY broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. SNY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.629) is normal, around the industry mean (-1.421). P/E Ratio (28.596) is within average values for comparable stocks, (21.700). SNY's Projected Growth (PEG Ratio) (27.976) is very high in comparison to the industry average of (5.738). SNY's Dividend Yield (0.169) is considerably higher than the industry average of (0.038). P/S Ratio (1.829) is also within normal values, averaging (4.033).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a producer of pharmaceutical products
Industry PharmaceuticalsMajor